GoodRx Holdings, Inc.: updates and filings

GDRXNASDAQTechnology · Services-Computer Processing & Data Preparation

Price

$3.02

November 19, 2026Market cap $1.1B

What Ploutos Investor adds for GoodRx

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 8 fiscal years, from 2018
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

14 days agoAround Nov 5, 2026 · for Q3 2026

last Aug 5, 2026next Nov 5, 2026

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 26, 2026 latest annualAug 5, 2026 latest quarterly
  • Nov 10, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 10, 2026Notice that the quarterly report will be filed late
    FormNT 10-Q
  • Nov 2, 2026Previous financial statements not to be relied on
    Form8-K
  • Aug 26, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Aug 5, 2026Officer or director change
    Form8-K
  • Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 5, 2026Results of operations
    Form8-K
  • Jun 18, 2026Shareholder vote
    Form8-K
  • May 6, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 6, 2026Results of operations
    Form8-K
  • Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 29, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 29, 2026Annual meeting proxy statement
    FormDEF 14A
  • Apr 24, 2026Officer or director change
    Form8-K
  • Apr 3, 2026Officer or director change
    Form8-K
  • Mar 27, 2026Officer or director change
    Form8-K
  • Mar 27, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Mar 18, 2026Change of auditor
    Form8-K
  • Mar 6, 2026Officer or director change
    Form8-K
  • Feb 27, 2026Officer or director change
    Form8-K
  • Feb 26, 2026Shares registered for employees
    FormS-8
  • Feb 26, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Feb 25, 2026Results of operations
    Form8-K
  • Dec 12, 2025Officer or director change
    Form8-K
  • Nov 4, 2025Quarterly reportfor the period to Sep 30, 2025
    Form10-Q

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 16, 2020.

The full analysis

What do GoodRx's filings show?

The filings are where every one of GoodRx's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.